Related Experiment Video
Updated: Jun 4, 2026

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration
Published on: April 27, 2018
Developing an effective gene therapy for prostate cancer: New technologies with potential to translate from the
Rupesh Dash1, Belal Azab, Xue-Ning Shen
1Department of Human and Molecular Genetics, Virginia Commonwealth University School of Medicine, Richmond, 23298, USA.
Abstract:
Prostate cancer is the second leading cause of cancer-related deaths in men in the U.S. At present, no single or combination therapy has shown efficacy in decreasing disease progression in patients with metastatic disease. A potentially viable approach for treating late-stage prostate cancer is gene therapy. Adenoviruses (Ad) are the most commonly used mode of gene delivery, but progress using this vector has been hampered by concerns over the safety and practicality of viruses including conditionally replicating Ads (CRAds), particularly for intravenous delivery, and the inefficiency of non-viral transfection techniques. Major challenges for effective gene therapy using Ads are the limited infectivity of regular Ad serotype 5 (Ad5) and the inability to specifically deliver the therapeutic directly into diseased tissue without trapping in the liver or elimination by the immune system. The shortcoming in using Ad5 is mostly attributed to a reduction in Coxsackie-adenovirus receptors (CAR) on the surface of cancer cells, which can be mitigated by generating tropism-modified Ads permitting CAR-independent infection of tumor cells. The limitations of systemic gene delivery can now be overcome by using a novel targeted-delivery approach such as ultrasound (US) contrast agents (microbubbles) to deliver effective therapeutic reagents, Ads, or recombinant proteins, combined with ultrasound-targeted microbubble destruction (UTMD), to develop a site-specific therapy in immune competent transgenic mouse models. These unique strategies for enhancing the efficacy of gene therapy provide a direct path to translation from the laboratory into the clinic for developing an effective gene therapy of prostate cancer.
Insights
Gene therapy offers a promising approach for advanced prostate cancer. Novel ultrasound-targeted microbubble destruction (UTMD) enhances gene delivery, overcoming limitations of traditional adenovirus vectors for effective, site-specific treatment.
Area of Science:
- Oncology
- Gene Therapy
- Biotechnology
Background:
- Prostate cancer is a leading cause of male cancer deaths, with limited effective treatments for metastatic disease.
- Current gene therapy approaches using adenoviruses face challenges including safety, efficiency, and targeted delivery.
- Limitations include adenovirus serotype 5 (Ad5) infectivity issues and off-target effects due to reduced Coxsackie-adenovirus receptors (CAR) on cancer cells.
Purpose of the Study:
- To investigate a novel targeted gene delivery system for prostate cancer therapy.
- To overcome the limitations of conventional adenoviral vectors for systemic gene delivery.
- To develop a site-specific gene therapy approach using ultrasound-targeted microbubble destruction (UTMD).
Main Methods:
- Utilized ultrasound (US) contrast agents (microbubbles) for targeted delivery of therapeutic reagents, including adenoviruses (Ad).
- Employed ultrasound-targeted microbubble destruction (UTMD) to achieve site-specific therapeutic effects.
- Tested the novel strategy in immune-competent transgenic mouse models of prostate cancer.
Main Results:
- The UTMD approach demonstrated potential for overcoming limitations of standard Ad5 vectors, such as CAR-dependent infection.
- This method allows for targeted delivery of therapeutic agents, potentially reducing off-target effects and immune system elimination.
- The strategy showed promise for enhancing gene therapy efficacy in a preclinical model.
Conclusions:
- Ultrasound-targeted microbubble destruction (UTMD) represents a viable strategy for enhancing targeted gene therapy delivery in prostate cancer.
- This novel approach addresses key challenges in adenoviral gene therapy, including infectivity and specificity.
- The findings suggest a direct translational path for developing effective gene therapies for prostate cancer from laboratory research to clinical application.
More Related Videos
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
09:37Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021
Related Concept Videos
Gene Therapy
Gene Therapy
Microorganisms in Medicine and Therapeutics
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...